Particle Measuring Systems Launches New Microbial Monitor
The BioCapt Single-Use STS device improves microbial sampling efficiency in isolators and RABS environments.
Updated on Oct. 21, 2026 in Life Sciences
Live Poll
Do you believe drug manufacturers should prioritize production efficiency over stricter environmental contamination controls?
Particle Measuring Systems has introduced the BioCapt Single-Use STS Microbial Monitor, designed to enable microbial sampling without interrupting production lines. The device utilizes advanced transfer technology to facilitate seamless active air monitoring within isolators and RABS.
Why it matters
The system aims to minimize contamination risks and handling efforts by eliminating the need for traditional cleaning and sterilization cycles. It also helps manufacturers maintain compliance with strict EU GMP Annex 1 requirements.
The device provides continuous active air monitoring for a duration of four hours at an airflow rate of 25 LPM. It operates using sterile-ready impactors that integrate with Getinge DPTE-BetaBag transfer technology.
The players
Particle Measuring Systems
The company is a leading manufacturer of particle counters and microbial monitoring instruments for cleanroom environments.
Getinge
This global medical technology firm specializes in sterile transfer systems, including the DPTE technology utilized by the new monitor.
The details
By utilizing Rapid Transfer Ports, the monitor allows for the introduction of consumables into sterile environments without requiring additional decontamination activities. This design streamlines workflows by allowing for continuous monitoring during active pharmaceutical manufacturing processes.
Timeline
October 21, 2026: Particle Measuring Systems launched the BioCapt Single-Use STS.
The Big Picture
The launch marks a shift toward closed-system monitoring that prioritizes automated compliance with EU GMP Annex 1. This move reflects a departure from manual, open-door sampling methods that historically introduced higher risks to sterile production zones.
Pharmaceutical manufacturers can now automate previously manual sampling processes, significantly reducing the time spent on cleanroom sterilization. This technology could lead to more efficient drug production cycles and higher standards of sterility in the manufacturing of clinical products.
The takeaway
Automating microbial monitoring within isolators significantly reduces human intervention in sensitive cleanroom environments. Manufacturers should evaluate their current sampling throughput against these new automated capabilities to optimize production uptime.
Further reading
Learn more about the latest innovations in pharmaceutical manufacturing by visiting the Life Sciences section.
Source note: This article includes information reported by AZoM.
Live Poll
Do you believe drug manufacturers should prioritize production efficiency over stricter environmental contamination controls?
